MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clml.2015.11.008

Медицинская библиотека · Clinical lymphoma, myeloma & leukemia · 2015

Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study.

Buckstein Rena, Fraser Graeme, Cheung Matthew, Kukreti Vishal, Kuruvilla John, Imrie Kevin, Piliotis Eugenia, Pond Gregory, Windsor Jolanta, Ghorab Zeina, Shuoprasad Kevin, Turner Ruth, Meyer Ralph M, Pritchard Kathy, Walker Scott, Levine Mark, Crump Michael

Клиническое исследование I фазыСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Alemtuzumab has single-agent activity in relapsed peripheral T cell lymphoma (PTL), but the optimal dose and/or schedule in combination with chemotherapy for first-line use is unknown. The primary objectives were to establish the maximally tolerated dose and pharmacokinetics (PK) of alemtuzumab combined in this way.

PATIENTS AND

METHODS

Adult patients with untreated CD52-positive (CD52(+)) PTL were enrolled in a phase I trial. Alemtuzumab was given subcutaneously in escalating doses and/or schedules in combination with CHOP (cyclophosphamide, adriamycin, vincristine and prednisone) using a 3+3 design. Trough PK of alemtuzumab were measured on day 1 of each 21-day cycle and B and T cell subsets were serially measured.

RESULTS

Twenty patients were enrolled across 4 dose levels. Dose-limiting toxicities necessitated expansion at 10 mg weekly (fatal tuberculosis reactivation) and 60 mg every 3 weeks (grade 4 thrombocytopenia) dose levels. Maximally tolerated dose was not reached. Ten patients developed asymptomatic cytomegalovirus reactivations at a median of 39 days (range, 4-99 days). Two patients developed fungal pneumonias. The overall and complete response rates were 68% and 37%, respectively. Highest day 1 alemtuzumab trough levels were achieved at 60 mg (1973 ng/mL), but with significant inter- and intradose variability. Lymphopenia at baseline was common and T cell recovery was significantly delayed.

CONCLUSION

With monitoring and prophylaxis, alemtuzumab 60 mg combined with CHOP showed activity in CD52(+) PTL and achieved the highest drug levels.

Для цитирования: Buckstein Rena, Fraser Graeme, Cheung Matthew, Kukreti Vishal, Kuruvilla John, Imrie Kevin, Piliotis Eugenia, Pond Gregory, Windsor Jolanta, Ghorab Zeina, Shuoprasad Kevin, Turner Ruth, Meyer Ralph M, Pritchard Kathy, Walker Scott, Levine Mark, Crump Michael. Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study.. Clinical lymphoma, myeloma & leukemia. 2015. DOI: 10.1016/j.clml.2015.11.008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.